# Molecular<sup>®</sup> Innovations

# **Human uPA Total Antigen ELISA Kit**

Catalog # HUPAKT-TOT

Strip well format. Reagents for up to 96 tests.

Rev: March 2017

#### **INTENDED USE**

Human uPA total antigen assay is intended for the determination quantitative of total urokinase plasminogen activator in human plasma, serum, urine, cell culture media, or tissue extracts. For research use only.

#### **BACKGROUND**

Urokinase plasminogen activator (uPA) is a serine protease that activates plasminogen to plasmin in the blood fibrinolytic system. It is also implicated in events related to cell invasion/migration [1].

#### **ASSAY PRINCIPLE**

Human uPA will bind to the capture antibody coated on the microtiter plate. Free and complexed enzyme will react with the capture antibody on the plate. After appropriate washing steps, polyclonal anti-human uPA primary antibody binds to the captured enzyme. Excess antibody is washed away and bound polyclonal antibody is then reacted with the secondary antibody conjugated to horseradish peroxidase. TMB substrate is used for color development at 450nm. A standard calibration curve is prepared along with the samples measured using dilutions of uPA.

#### **REAGENTS PROVIDED**

- •96-well antibody coated microtiter strip (removable wells 8x12) containing anti-human uPA antibody, blocked and dried.
- •10X Wash buffer: 1 bottle of 50ml
- Human uPA standard: 1 vial lyophilized standard
- Anti-human uPA primary antibody: 1 vial lyophilized polyclonal antibody
- Anti-rabbit horseradish peroxidase secondary antibody: 1 vial concentrated HRP labeled antibody
- •TMB substrate solution: 1 bottle of 10ml solution

#### STORAGE AND STABILITY

Store all kit components at 4°C upon arrival. Return any unused microplate strips to the plate pouch with desiccant. Reconstituted standards and primary may be stored at -80°C for later use. Do not freeze-thaw the standard and primary antibody more than once. Store all other unused kit components at 4°C. This kit should not be used beyond the expiration date.

#### OTHER REAGENTS AND SUPPLIES REQUIRED

- •Microtiter plate shaker capable of 300 rpm uniform horizontally circular movement
- Manifold dispenser/aspirator or automated microplate washer
- •Microplate reader capable of measuring absorbance at 450 nm (
- Pipettes and Pipette tips
- Deionized or distilled water
- Polypropylene tubes for dilution of standard
- Paper towels or laboratory wipes
- 1N H₂SO₄ or 1N HCl
- Bovine Serum Albumin Fraction V (BSA)
- Tris(hydroxymethyl)aminomethane (Tris)
- Sodium Chloride (NaCl)

# **PRECAUTIONS**

- •FOR LABORATORY RESEARCH USE ONLY. NOT FOR DIAGNOSTIC USE.
- •Do not mix any reagents or components of this kit with any reagents or components of any other kit. This kit is designed to work properly as provided.
- Always pour peroxidase substrate out of the bottle into a clean test tube. Do not pipette out of the bottle as contamination could result.
- •Keep plate covered except when adding reagents, washing, or reading.
- •DO NOT pipette reagents by mouth and avoid contact of reagents and specimens with skin.
- •DO NOT smoke, drink, or eat in areas where specimens or reagents are being handled.

#### PREPARATION OF REAGENTS

- •TBS buffer: 0.1M Tris, 0.15M NaCl, pH 7.4 •Blocking buffer (BB): 3% BSA (w/v) in TBS
- •1X Wash buffer: Dilute 50ml of 10X wash buffer concentrate with 450ml of deionized water.

# **SAMPLE COLLECTION**

Collect plasma using EDTA or citrate as an anticoagulant. Centrifuge for 15 minutes at 1000xg within 30 minutes of collection. Assay immediately or aliquot and store at ≤ -20°C. Avoid repeated freeze-thaw cycles.

#### **ASSAY PROCEDURE**

Perform assay at room temperature. Vigorously shake plate (300rpm) at each step of the assay.

## **Preparation of Standard**

Reconstitute standard by adding 1ml of blocking buffer directly to the vial and agitate gently to completely dissolve contents. This will result in a 500ng/ml standard solution.

Dilution table for preparation of human uPA standard:

bilation table for preparation of name at 77 standard.								
uPA concentration (ng/ml)	Dilutions							
50	900µl (BB) + 100µl (from vial)							
20	600µl (BB) + 400µl (50ng/ml)							
10	500µl (BB) + 500µl (20ng/ml)							
5	500µl (BB) + 500µl (10ng/ml)							
2	600µl (BB) + 400µl (5ng/ml)							
1	500µl (BB) + 500µl (2ng/ml)							
0.5	500µl (BB) + 500µl (1ng/ml)							
0.2	600µl (BB) + 400µl (0.5ng/ml)							
0.1	500µl (BB) + 500µl (0.2ng/ml)							
0	500μl (BB) Zero point to							
U	determine background							

NOTE: DILUTIONS FOR THE STANDARD CURVE AND ZERO STANDARD MUST BE MADE AND APPLIED TO THE PLATE IMMEDIATELY.

# **Standard and Unknown Addition**

Remove microtiter plate from bag and add  $100\mu l$  uPA standards (in duplicate) and unknowns to wells. Carefully record position of standards and unknowns. Shake plate at 300rpm for 30 minutes. Wash wells three times with  $300\mu l$  wash buffer. Remove excess wash by gently tapping plate on paper towel or kimwipe.

NOTE: The assay measures uPA antigen in the 0.1-50 ng/ml range. If the unknown is thought to have high uPA levels, dilutions may be made in blocking buffer or similar biological fluid devoid of uPA.

## **Primary Antibody Addition**

Reconstitute primary antibody by adding 10ml of blocking buffer directly to the vial and agitate gently to completely dissolve contents. Add 100 $\mu$ l to all wells. Shake plate at 300rpm for 30 minutes. Wash wells three times with 300 $\mu$ l wash buffer. Remove excess wash by gently tapping plate on paper towel or kimwipe.

# **Secondary Antibody Addition**

Briefly centrifuge vial before opening. Dilute  $2\mu l$  of conjugated secondary antibody in 10ml of blocking buffer and add 100 $\mu l$  to all wells. Shake plate at 300rpm for 30 minutes. Wash wells three times with 300 $\mu l$  wash buffer. Remove excess wash by gently tapping plate on paper towel or kimwipe.

# Substrate Incubation

Add 100 $\mu$ l TMB substrate to all wells and shake plate for 2-10 minutes. Substrate will change from colorless to different strengths of blue. Quench reaction by adding 50 $\mu$ l of 1N H<sub>2</sub>SO<sub>4</sub> or HCl stop solution to all wells when samples are visually in the same range as the standards. Add stop solution to wells in the same order as substrate upon which color will change from blue to yellow. Mix thoroughly by gently shaking the plate.


#### Measurement


Set the absorbance at 450nm in a microtiter plate spectrophotometer. Measure the absorbance in all wells at 450nm. Subtract zero point from all standards and unknowns to determine corrected absorbance ( $A_{450}$ ).

# **Calculation of Results**

Plot  $A_{450}$  against the amount of uPA in the standards. Fit a straight line through the linear points of the standard curve using a linear fit procedure if unknowns appear on the linear portion of the standard curve. Alternatively, create a standard curve by analyzing the data using a software program capable of generating a four parameter logistic (4PL) curve fit. The amount of uPA in the unknowns can be determined from this curve. If samples have been diluted, the calculated concentration must be multiplied by the dilution factor.

A typical standard curve (EXAMPLE ONLY):





#### **EXPECTED VALUES**

The concentration of uPA antigen in human plasma has been reported to be  $3.5 \pm 1.4$  ng/ml (n=54) [2]. Culture media of fibroblasts, endothelial, and kidney cells showed antigen levels of 1.2, 23 and 65 ng/ml, respectively [2]. The uPA antigen level in human bile is reported as 0.705 ng/ml [3].

Detergent extracts of human tumor tissues had the following uPA antigen levels [4]:

Tumor Tissue	Mean	Range	n
Lung	6.28	3.33-18.23	6
Cervix	5.03	2.33-8.72	6
Colon	3.65	2.30-8.80	6
Melanoma	1.04	0.62-1.77	6
Breast	2.67	0.00-8.96	9

Abnormalities in uPA levels have been reported in the following conditions:

- •Venous Thrombosis: Low levels of uPA is associated with clot formation [5].
- •Inflammatory Disease: Low levels of uPA may aggravate this condition [6].

# PERFORMANCE CHARACTERISTICS

**Sensitivity:** The minimum detectable dose (MDD) was determined by adding two standard deviations to the mean optical density value of twenty zero standard replicates (range  $OD_{450}$ : 0.087-0.098) and calculating the corresponding concentration. The MDD was 0.019 ng/ml.

**Intra-assay Precision:** Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

Sample	1	2	3
n	20	20	20
Mean (ng/ml)	0.751	3.739	9.692
Standard Deviation	0.021	0.268	0.300
CV (%)	2.77	7.16	3.09

**Inter-assay Precision:** These studies are currently in progress. Please contact us for more information.

**Recovery:** These studies are currently in progress. Please contact us for more information.

**Linearity:** To assess the linearity of the assay, pooled citrated human plasma samples containing normal concentrations of antigen were serially diluted to produce samples with values within the dynamic range of the assay.

Sample	1:2	1:4
n	4	4
Average %	100	103
of Expected		
Range	94-107%	95-111%

**Specificity:** This assay recognizes natural and recombinant human uPA. Pooled normal plasma from rhesus monkey was assayed and significant cross-reactivity was observed. Pooled normal plasma from mouse, rat, dog and sheep were assayed and no significant cross-reactivity was observed. Pooled normal plasma from rabbit resulted in significant color development.

**Sample Values:** Samples were evaluated for the presence of the antigen at varying dilutions.

Sample Type	Dilution	Mean (ng/mL)
Citrate Plasma	Undiluted	2.60
Citiate Plasifia	1:2	2.60

# **DISCLAIMER**

This information is believed to be correct but does not claim to be all-inclusive and shall be used only as a guide. The supplier of this kit shall not be held liable for any damage resulting from handling of or contact with the above product.

# **REFERENCES**

- 1. Kjøller L: Biol Chem. 2002, 383:5-19.
- 2. Binnema DJ, et al.: Thromb Res. 1986, 43(5):569-577.
- 3. Kondera-Anasz Z, *et al.*: Med Sci Monit. 2000, 6(3):616-617.
- 4. Ferrier CM, *et al.*: Brit J of Can. 1999, 79(9/10):1534-1541.
- 5. Singh I, et al.: Circulation. 2003, 107(6): 869-875.
- 6. Yang YH, et al.: J Immunol. 2001, 167(2):1047-1052

# **Example of ELISA Plate Layout**

96 Well Plate: 20 Standard wells, 76 Sample wells

	1	2	3	4	5	6	7	8	9	10	11	12
Α	0	0.1 ng/ml	0.2 ng/ml	0.5 ng/ml	1 ng/ml	2 ng/ml	5 ng/ml	10 ng/ml	20 ng/ml	50 ng/ml		
В	0	0.1 ng/ml	0.2 ng/ml	0.5 ng/ml	1 ng/ml	2 ng/ml	5 ng/ml	10 ng/ml	20 ng/ml	50 ng/ml		
С							2					
D						OY						
E						5)		80			5	
F							7					
G						<b>\</b>						
н			01					241				